Stem Cell Therapy For Female Infertility In India

What causes female infertility?

Female infertility usually falls into one of these categories:

• Ovarian factors — diminished ovarian reserve, premature ovarian insufficiency, or PCOS affecting egg quality and ovulation
• Uterine factors — thin endometrial lining, uterine fibroids, Asherman’s syndrome (uterine scarring), or congenital uterine abnormalities
• Tubal factors — blocked or damaged fallopian tubes, often from past infection or endometriosis
• Hormonal factors — thyroid disorders, elevated prolactin, or other endocrine imbalances affecting ovulation
• Age-related decline — natural reduction in egg quantity and quality after the mid-30s
• Unexplained infertility — no identifiable cause found despite full evaluation

This distinction matters clinically: stem cell research in this area has focused mainly on ovarian and uterine-lining causes, not tubal blockages or structural abnormalities, which typically require surgical or IVF-based approaches instead.

What are symptoms of female infertility?

Infertility itself often has no standalone symptoms — it’s usually identified through the absence of pregnancy despite trying. However, some of the following may point to an underlying cause worth evaluating:

• Irregular, absent, or very heavy menstrual cycles
• Pain during periods or intercourse
• Signs of hormonal imbalance (unusual hair growth or loss, acne, weight changes)
• Recurrent early miscarriage

If you notice any of these, the next step is diagnostic testing — not stem cell therapy directly — to identify the specific cause first.

How is female infertility diagnosed?

Before any treatment plan is discussed, we require a proper diagnostic work-up, which typically includes:

• Hormonal panel — AMH, FSH, LH, thyroid, and prolactin levels
• Ovarian reserve assessment — antral follicle count via transvaginal ultrasound
• Uterine evaluation — hysteroscopy or saline sonogram to check endometrial lining thickness and uterine structure
• Tubal patency test — HSG (hysterosalpingogram), if tubal blockage is suspected
• Partner’s semen analysis, since infertility can involve both partners

Your reports are reviewed by our specialist team before any stem cell-based protocol is proposed — this isn’t a treatment offered without a confirmed, specific diagnosis behind it.

Stem Cell Treatment for Female Infertility India

Stem cell therapy for female infertility uses mesenchymal stem cells — typically sourced from bone marrow, adipose tissue, or umbilical cord tissue — to target specific, diagnosed causes of infertility such as diminished ovarian reserve or a thin endometrial lining. It is administered by our specialists at Viezec’s accredited facility in India as a supportive option alongside conventional fertility treatment, not as a replacement for IVF or standard reproductive medicine. It is not a guaranteed path to pregnancy, and eligibility depends entirely on your specific diagnosis.

How Does Stem Cell Therapy Work for Female Infertility?

Mesenchymal stem cells (MSCs) are being studied for their ability to:

• Support ovarian tissue — potentially improving the ovarian micro-environment in cases of diminished ovarian reserve, through paracrine (signalling) effects rather than by creating new eggs
• Improve endometrial lining — research suggests MSCs may help thicken and vascularize a thin uterine lining, improving the chance of embryo implantation
• Reduce local inflammation — in conditions like Asherman’s syndrome (uterine scarring), MSCs are being explored for their anti-inflammatory and tissue-repair properties

Cells are collected from the patient (autologous) or from screened donor tissue (allogeneic, e.g., umbilical cord), processed under lab conditions, then administered via intraovarian or intrauterine injection depending on the specific protocol your specialist selects.

Who Is a Candidate?

You may be evaluated as a candidate if you have a confirmed diagnosis of:

• Diminished ovarian reserve (low AMH, poor response to previous IVF cycles)
• Premature ovarian insufficiency
• Thin endometrial lining (typically under 7mm despite hormonal support)
• Asherman’s syndrome / uterine scarring

You are not likely to be a candidate if your infertility is due to tubal blockage, structural abnormalities, or male-factor infertility alone — these require different treatment pathways, and we will tell you this directly during evaluation rather than propose an unsuitable protocol.

What to Expect: The Treatment Process

1. Consultation & diagnostic review — your existing reports (hormonal panel, ultrasound, HSG) are reviewed by our specialist team
2. Cell sourcing — bone marrow or adipose tissue collection (autologous) under local anaesthesia, or use of screened donor cord tissue
3. Lab processing — cells are isolated and prepared under controlled lab conditions
4. Administration — intraovarian or intrauterine delivery, depending on your specific protocol
5. Follow-up monitoring — hormonal and ultrasound follow-up over the following weeks to assess response

Most patients require a 5–7 day in-country stay for evaluation and treatment, with follow-up monitoring continuing remotely afterward.

Improvements Seen After Stem Cell Treatment for Female Infertility

Current research on stem cell therapy for female infertility shows measurable improvements in specific fertility markers — such as AMH (ovarian reserve), follicle count, and endometrial lining thickness — in women with diminished ovarian reserve, premature ovarian insufficiency, or thin endometrium. It is not a guaranteed path to pregnancy, and results vary by individual diagnosis, age, and underlying cause.

Ovarian Reserve Markers

For women with diminished ovarian reserve (DOR) or premature ovarian insufficiency (POI), the improvements most consistently reported in research relate to ovarian function markers rather than pregnancy alone:

• AMH (Anti-Müllerian Hormone): A 2024 systematic review and meta-analysis of 38 studies covering over 2,000 women with diminished ovarian reserve found that AMH levels rose significantly while FSH levels decreased significantly following ovarian PRP/stem-cell-factor treatment, with the increase in AMH becoming more pronounced at the 3-month mark than at 1 month. nih
• Follicle count and oocyte activation: A 2025 retrospective clinical study from IVIRMA Alicante evaluated women with diminished ovarian reserve, poor ovarian response, and premature ovarian insufficiency using stem cell mobilization combined with an intraovarian platelet-rich plasma injection, tracking antral follicle count and pregnancy rate as outcome measures, with a rise of at least 3 follicles counted as a positive response. nihContemporary OB/GYN
• Underlying ovarian function: Animal-model research summarized in a 2024 review notes that stem cell therapy has shown potential to help reverse diminished ovarian endocrine function and support restored fertility in POI patients, though this remains an area of active research rather than settled clinical fact. MDPI

Endometrial Lining Improvements

For women whose infertility relates to a thin or damaged uterine lining (including Asherman’s syndrome), a 2025 review of ADSC (adipose-derived stem cell) research found that administering these cells directly into the uterus improved endometrial thickness, blood vessel formation, and receptivity, with some studies also reporting increased implantation and pregnancy rates in women with thin lining or Asherman’s syndrome. nih

What This Means for Monitoring, Not Just Outcomes

At Viezec’s Delhi facility, improvement is tracked through objective markers rather than self-reported symptoms alone:

What the Research Does Not Yet Show

We believe this needs to be stated plainly: most current evidence comes from observational studies, small clinical cohorts, or animal models rather than large randomized controlled trials and most reviewers note that large-scale, high-quality studies are still needed given considerable variability between the existing studies. Stem cell therapy is not established as a treatment that reverses infertility for every cause, and it does not replace IVF or standard reproductive medicine where those are already indicated. Your treating specialist will confirm, based on your specific hormonal and ultrasound findings, whether measurable improvement is a realistic goal in your case. PubMed Central

Quick FAQ

Does stem cell therapy guarantee pregnancy?
No. It is researched as a way to potentially improve ovarian or uterine markers; pregnancy depends on many additional factors your specialist will assess individually.

How soon are improvements typically checked?
Most protocols recheck hormonal and ultrasound markers at 1, 3, and 6 months post-treatment.

Does this work for all causes of infertility?
No — current research focuses mainly on diminished ovarian reserve, premature ovarian insufficiency, and thin endometrial lining, not tubal blockage or structural abnormalities.

Our Promise

Viezec is committed to transparent, evidence-based regenerative medicine care — not overstated promises. Here is what that means in practice:

We commit to:

• No cure claims. Stem cell therapy is offered as a researched, supportive treatment option — never marketed as a guaranteed cure for female infertility or any condition we treat.
• Diagnosis before treatment. No stem cell protocol is proposed without a completed hormonal, ovarian, and uterine evaluation confirming you are a suitable candidate.
• Named, credentialed medical oversight. Every treatment plan is reviewed by a qualified reproductive/regenerative medicine specialist — not an unnamed “medical team.”
• Regulatory transparency. Our stem cell protocols operate within India’s ICMR guidelines for investigational stem cell use. We disclose which regulatory framework applies to your specific treatment when asked, directly and in writing.
• Accredited facilities. Our treatment and cell-processing facilities hold NABH and NABL accreditation, which you can independently verify through each body’s public registry using our registration number.
• Written, itemized cost estimates. No flat public pricing — because cost genuinely varies by diagnosis and protocol — but a clear, written estimate is provided after your medical evaluation, before you commit to anything.
• Location and access clarity. Our facility is based in [Delhi, India], with dedicated support for international patients, including visa assistance, accommodation coordination, and remote follow-up for 6–12 months post-treatment.
• Honest evidence communication. Where clinical evidence is still developing (as it is for stem cell therapy in female infertility), we say so directly, and cite the specific studies our approach is based on, rather than implying stronger proof than currently exists.

In short: if a clinic won’t show you its accreditation numbers, name your treating physician, or give you a written cost estimate before treatment, that’s a signal to ask more questions. We built this page so you don’t have to take our word for it — you can verify each of the above independently.

Treatment Results Of Female Infertility at Viezec

Stem cell therapy for female infertility at Viezec (Delhi, India) is used to support ovarian function in specific cases — primarily diminished ovarian reserve and premature ovarian insufficiency (POI) — by improving hormone levels and follicle activity. It is not a guaranteed pregnancy treatment; results vary by diagnosis, age, and ovarian reserve at baseline, and are evaluated case-by-case by our reproductive specialist team.

What does current research show?

• A 2024 systematic review and meta-analysis (Hu et al., Archives of Gynecology and Obstetrics) of clinical and animal studies found stem cell therapy improved hormone levels, follicle count, and menstrual cycle regularity in POI patients, though clinical-study evidence remains smaller in scale than animal-study evidence.
• A 2023 review (Frontiers in Endocrinology) of small clinical trials reported that mesenchymal stem cell (MSC) therapy was associated with improved menstruation and ovarian function in some women with premature ovarian failure, with a good safety profile over 12+ months of follow-up.
• Individual case reports, including one by Edessy et al., have documented live births following bone-marrow-derived stem cell transplantation into the ovaries in POI patients — noted in research as a meaningful but not yet consistently reproducible outcome.
• Ongoing registered clinical trials (ClinicalTrials.gov) continue to evaluate hormone and follicular response as primary safety and effectiveness measures — this remains an active area of research, not a finalized, standardized treatment.

What results can realistically be expected?

Who is this typically considered for?

• Women with diminished ovarian reserve (DOR) confirmed via AMH and antral follicle count
• Women with premature ovarian insufficiency (POI), diagnosed through hormone panel testing
• Women with a thin endometrial lining affecting implantation, evaluated separately from ovarian causes
• Not typically indicated for tubal blockage or structural abnormalities — these usually require surgical or IVF-based approaches instead

Is this a replacement for IVF or fertility medication?

No. Stem cell therapy at Viezec is offered as a complementary, physician-supervised option alongside — not instead of — standard fertility evaluation and treatment. Your reproductive specialist will advise whether it’s appropriate to combine with or precede other fertility treatments based on your specific diagnosis.

Testimonials

Ananya P. – Delhi, India – February 2020 – ⭐⭐⭐⭐☆
“I was struggling with infertility for years. After Viezec’s stem cell therapy, my ovarian function improved, and I finally conceived naturally.”

Emma W. – London, UK – July 2020 – ⭐⭐⭐⭐⭐
“Doctors told me IVF would be difficult. Post stem cell treatment at Viezec, my cycles normalized, and I now have a healthy pregnancy.”

Aisha H. – Cairo, Egypt – November 2020 – ⭐⭐⭐⭐☆
“I faced repeated miscarriages due to poor uterine lining. Viezec’s therapy improved my endometrial health, and I carried my baby to term.”

Isabella C. – Rome, Italy – March 2021 – ⭐⭐⭐⭐⭐
“After years of failed fertility treatments, stem cell therapy at Viezec helped restore my fertility. Today, I’m blessed with a daughter.”

Sofia K. – Athens, Greece – September 2021 – ⭐⭐⭐⭐☆
“I had low ovarian reserve. After Viezec’s stem cell therapy, my egg quality improved, and I was able to undergo a successful IVF.”

Hannah T. – Toronto, Canada – February 2022 – ⭐⭐⭐⭐⭐
“Infertility left me hopeless. Thanks to Viezec, I regained hormonal balance, and within months, I conceived after years of struggle.”

Fatima Z. – Dubai, UAE – August 2022 – ⭐⭐⭐⭐☆
“I was diagnosed with premature ovarian failure. After stem cell therapy at Viezec, my menstrual cycles resumed, and I now have new hope.”

Maria G. – Madrid, Spain – April 2023 – ⭐⭐⭐⭐⭐
“My infertility journey was long and painful. Post treatment at Viezec, my uterus healed, and I delivered a healthy baby boy.”

Chloe S. – Sydney, Australia – October 2023 – ⭐⭐⭐⭐☆
“Stem cell therapy at Viezec gave me back the chance to be a mother. My ovarian function improved, and I conceived successfully.”

Layla H. – Istanbul, Turkey – May 2025 – ⭐⭐⭐⭐⭐
“Infertility had broken my confidence. After Viezec’s therapy, I achieved pregnancy, and I’m now enjoying motherhood after years of waiting.”

Female Infertility Happy Patient Videos

Female Infertility Stem Cell Treatment..Watch Video

Treatment Disclaimer

Is stem cell therapy a guaranteed cure for female infertility?

No. Stem cell therapy for female infertility is not a guaranteed cure, and no clinic — including Viezec — can promise pregnancy as an outcome. It is offered as a supportive, investigational option for specific causes of infertility, based on your individual diagnosis, and should not be understood as a replacement for established treatments like IVF where those are medically more appropriate.

What does the current evidence show?

Research into stem cell therapy for conditions like diminished ovarian reserve and thin endometrial lining is still evolving. Some published studies report improvements in ovarian markers or endometrial thickness in selected patients, while others show limited or inconsistent results. This is an active area of clinical research, not an established standard-of-care treatment recognized by major fertility bodies (such as ASRM or ESHRE) at this time.

Who is this treatment intended for?

Stem cell therapy at Viezec, New Delhi, India, is considered only after a full diagnostic work-up confirms a specific underlying cause — such as diminished ovarian reserve or thin endometrial lining — where existing evidence is more directly relevant. It is not offered as a first-line treatment, and it is not appropriate for every cause of infertility (for example, tubal blockage or structural abnormalities typically require different approaches).

What results can I realistically expect?

Individual results vary based on age, diagnosis, ovarian reserve, and overall health. We do not publish blanket improvement percentages, because outcomes differ significantly from patient to patient. During your consultation, our specialist will discuss what is realistic for your specific case based on your medical reports — not a generic success rate.

Who oversees treatment decisions?

All treatment plans are reviewed and overseen by our named treating specialist team based at our facility in New Delhi, India, following evaluation of your hormonal panel, ovarian reserve assessment, and uterine evaluation. No protocol is recommended without this evaluation.

Is this treatment regulated?

Stem cell therapies in India fall under specific regulatory frameworks depending on the cell type and application. We encourage every patient — whether considering treatment in India or elsewhere — to ask directly which regulatory framework applies and to verify the facility’s accreditation before proceeding.

Where can I get a specific answer for my case?

Because infertility has many possible causes, general information on this page cannot replace an individual medical evaluation. Book a consultation with our specialist team in New Delhi to review your reports and discuss whether you are a suitable candidate.